Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2019-05-13
DOI
10.1080/00365521.2019.1594356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
- (2019) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs
- (2018) Ingvar Bjarnason et al. GASTROENTEROLOGY
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
- (2018) Yuichiro Yasuda et al. INTERNAL MEDICINE
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
- (2018) Kati Choi et al. INFLAMMATORY BOWEL DISEASES
- Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
- (2018) Daniel H Johnson et al. Journal for ImmunoTherapy of Cancer
- Nivolumab-associated nausea and vomiting as an immune adverse event
- (2017) Yiwen Shi et al. EUROPEAN JOURNAL OF CANCER
- Acute hemorrhagic gastritis after nivolumab treatment
- (2017) Masanori Kobayashi et al. GASTROINTESTINAL ENDOSCOPY
- Immune modulator-induced changes in the gastrointestinal tract
- (2017) Prashant Bavi et al. HISTOPATHOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
- (2017) Michael Dougan Frontiers in Immunology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Managing Adverse Events With Immune Checkpoint Agents
- (2016) Ramona Dadu et al. CANCER JOURNAL
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’
- (2016) Raul S Gonzalez et al. HISTOPATHOLOGY
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- (2008) R. L. Johnston et al. DIGESTIVE DISEASES AND SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now